Browse diseases

… morbidity and mortality in a broad population of patients with pulmonary arterial hypertension (PAH), including those with PAH associated with systemic sclerosis (S…

…Background Pulmonary hypertension (PH) associated with lung disease entails a poor prognosis. There is concern about the potential …

…sim MT. Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension. Trends Pharmacol. Sci. 2021;42:510–513Osei-Wusuansa M, Mohamme…

…e II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2. Trials. 2024;25(1):680.Abstract 1…

…Rationale Pulmonary arterial hypertension (PAH) is a progressive, fatal cardiovascular that develops as a resul…

…Abstract Pulmonary arterial hypertension (PAH) is a fatal cardiovascular disorder characterized by vascular ob…

…Background Pulmonary arterial hypertension (PAH) is a progressive and fatal disease, leading to right ventricula…

…tion Pulmonary arterial hypertension (PAH) develops in 6–12% of systemic sclerosis (SSc) and is a major cause of morbidity and mortality. Current guidel…

… VVDs are commonly used in SSc to treat digital ulcers (DU) and Raynaud’s phenomenon, we investigated the effectiveness of VVD on the primary preven…

…s (SSc) is associated with significant morbidity and mortality. Pulmonary arterial hypertension (PAH) represents a negative prognostic factor, with a 3-year survival…

…monary arterial hypertension (PAH) is a major cause of death in systemic sclerosis (SSc) and, despite significant advances, still responds poorly to vas…

… arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). PAH is typically considered as a late complication, but some e…